Mode
Text Size
Log in / Sign up
Phase 1 Completed N=30 Randomized Quadruple-blind Treatment

The Efficacy of Doxazosin for Cocaine Users

Cocaine Dependence
Source: ClinicalTrials.gov NCT00880997 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcomePrimary: Cocaine Negative Urines — 10; 35; 14 percentage of cocaine-negative urines

Summary

Doxazosin, an alpha 1-adrenergic receptor, may play an important role in cocaine addiction in humans. This study will evaluate the effectiveness of doxazosin in preventing drug relapse among cocaine dependent participants.

Outcome Measures

OutcomeResultp-value
PRIMARY
Cocaine Negative Urines
10; 35; 14
SECONDARY
Weeks of Abstinence
0; 44; 7
SECONDARY
# of Participants That Completed the Study
6; 6; 5
SECONDARY
Adverse Events
26; 9; 23

Eligibility Criteria

Inclusion Criteria

  • Meets DSM-IV diagnosis criteria for cocaine dependence, as determined by self-reported use of cocaine at least once weekly for at least 1 month prior to study entry; a positive urine test for cocaine; and a score greater than 3 on the Severity of Dependence Scale
  • If female, willing to use contraception throughout the study

Exclusion Criteria

  • Meets DSM-IV diagnosis criteria for dependence on any drugs other than cocaine, or tobacco
  • Current major psychiatric illness, including schizophrenia, bipolar disorder, or other psychotic disorder
  • Current suicidal or homicidal ideation
  • Current use of a prescribed psychotropic medication that cannot be discontinued
  • History of or current major medical illness, including major heart, kidney, endocrine, or liver disorder; abnormal liver function (SGOT or SGPT levels three times greater than normal); or high blood pressure or low blood pressure
  • High risk factor for heart disease, seizure disorders, or any illness for which disulfiram or methadone treatment would be inadvisable
  • Currently taking metronidazole or clotrimazole
  • Pregnant or breastfeeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00880997). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search